Analysts think SKYE stock price could increase by 1232%
Apr 10, 2025, 11:25 AM
33.21%
What does SKYE do
Skye Bioscience, a San Diego-based biopharmaceutical company, focuses on cannabinoid-based therapeutics for metabolic disorders and inflammation. Its Phase 2 candidates include nimacimab for obesity and SBI-100 OE for glaucoma.
8 analysts think SKYE stock price will increase by 1232.09%. The current median analyst target is $17.85 compared to a current stock price of $1.34. The lowest analysts target is $14.14 and the highest analyst target is $22.05.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.